Drugs / DFV890
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05552469 | May 2023 → Jan 2027 expected | myeloid neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06097663 | Feb → Oct 2024 | clonal hematopoiesis of indeterminate potential, coronary artery disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT06031844 | Oct 2023 → Dec 2024 | coronary artery disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04886258 | Sep 2021 → Dec 2024 | osteoarthritis, knee | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04868968 | Sep 2021 → Dec 2022 | familial cold autoinflammatory syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04382053 | May → Dec 2020 | pneumonia | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFV890 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06097663 ↗ |
| Action | Inhibit | “DFV890: a new oral NLRP3 inhibitor” PMID 36104613 ↗ Sep 2022 |
| Route | Oral | “orally/nasogastrically administered” NCT04382053 ↗ |
| Route | Other | “orally/nasogastrically administered” NCT04382053 ↗ |
| Target | NLRP3 | “DFV890: a new oral NLRP3 inhibitor” PMID 36104613 ↗ Sep 2022 |